Skip to main content
U.S. flag

An official website of the United States government

Milestone 9.J

AD Related Dementias – Specific

Longitudinal antemortem LBD characterization.

Success Criteria

  • Evaluate existing LBD biomarker efforts, including systematic assessments of their impact on identifying pre-dementia LBD and prodromal or at-risk for LBD patients.
  • Informed by this evaluation, initiate at least one new study designed to identify pre-dementia LBD and prodromal or at-risk for LBD patients.
  • Ensure studies collect and share standardized clinical and neuropsychological data.

Summary of Key Accomplishments

In 2020, NIH-funded investigators helped lead an international consensus effort to define research criteria for diagnosing prodromal dementia with Lewy bodies (DLB), which will help to advance standardization of early LBD biomarkers. For example, several funded awards are evaluating a biomarker test that uses a simple skin biopsy to detect abnormal LBD-associated alpha-synuclein clumps in individuals with LBD and with prodromal LBD.

NIA and NINDS jointly funded the North American Prodromal Synucleinopathy Consortium for REM Sleep Behavior Disorder which is collecting longitudinal clinical, neuroimaging and biospecimen data on over 300 individuals with REM sleep behavior disorder, an important prodromal risk factor for the development of LBD.

The Parkinson's Disease Biomarkers Program (PDBP) and the National Alzheimer's Coordinating Center (NACC) continue to enroll individuals with LBD using a similar standard clinical assessment protocol designed specifically for this group that over 50 participating sites are required to use; all data is shared with interested researchers.

This information is current as of July 2022.

Research Implementation Area
AD Related Dementias - Specific
In Progress

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Relevant Recommendations

An official website of the National Institutes of Health